58,200 Shares in Cellebrite DI Ltd. (NASDAQ:CLBT) Bought by MYDA Advisors LLC

MYDA Advisors LLC purchased a new stake in Cellebrite DI Ltd. (NASDAQ:CLBT) during the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 58,200 shares of the company’s stock, valued at approximately $1,282,000.

Other institutional investors have also modified their holdings of the company. FMR LLC raised its position in Cellebrite DI by 89.1% during the fourth quarter. FMR LLC now owns 10,621,344 shares of the company’s stock valued at $233,988,000 after acquiring an additional 5,004,587 shares in the last quarter. True Wind Capital Management L.P. increased its holdings in shares of Cellebrite DI by 18.2% during the 4th quarter. True Wind Capital Management L.P. now owns 13,861,007 shares of the company’s stock valued at $305,358,000 after purchasing an additional 2,130,386 shares in the last quarter. Invesco Ltd. purchased a new stake in Cellebrite DI during the fourth quarter worth $32,700,000. Principal Financial Group Inc. acquired a new stake in Cellebrite DI during the third quarter valued at $23,402,000. Finally, Lord Abbett & CO. LLC acquired a new position in shares of Cellebrite DI in the third quarter worth about $11,523,000. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Cellebrite DI Stock Down 0.7 %

Shares of CLBT opened at $18.90 on Friday. The firm’s fifty day moving average is $18.99 and its two-hundred day moving average is $20.08. The stock has a market cap of $4.53 billion, a PE ratio of -13.60, a price-to-earnings-growth ratio of 4.27 and a beta of 1.44. Cellebrite DI Ltd. has a 52-week low of $10.25 and a 52-week high of $26.30.

Cellebrite DI (NASDAQ:CLBT) last released its earnings results on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. As a group, research analysts anticipate that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. Lake Street Capital lifted their price target on Cellebrite DI from $17.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, February 14th. Needham & Company LLC restated a “buy” rating and issued a $28.00 price objective on shares of Cellebrite DI in a research report on Wednesday, April 2nd. Finally, JPMorgan Chase & Co. increased their target price on Cellebrite DI from $24.00 to $28.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, Cellebrite DI has an average rating of “Buy” and a consensus price target of $23.43.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.